Cargando…
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
BACKGROUND: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452802/ https://www.ncbi.nlm.nih.gov/pubmed/31040709 http://dx.doi.org/10.2147/DMSO.S188705 |
_version_ | 1783409348405362688 |
---|---|
author | Hinnen, Deborah Kruger, Davida F |
author_facet | Hinnen, Deborah Kruger, Davida F |
author_sort | Hinnen, Deborah |
collection | PubMed |
description | BACKGROUND: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. PURPOSE: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. CONCLUSION: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions. |
format | Online Article Text |
id | pubmed-6452802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64528022019-04-30 Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials Hinnen, Deborah Kruger, Davida F Diabetes Metab Syndr Obes Review BACKGROUND: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. PURPOSE: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. CONCLUSION: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions. Dove Medical Press 2019-04-04 /pmc/articles/PMC6452802/ /pubmed/31040709 http://dx.doi.org/10.2147/DMSO.S188705 Text en © 2019 Hinnen and Kruger. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Hinnen, Deborah Kruger, Davida F Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
title | Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
title_full | Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
title_fullStr | Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
title_full_unstemmed | Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
title_short | Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
title_sort | cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452802/ https://www.ncbi.nlm.nih.gov/pubmed/31040709 http://dx.doi.org/10.2147/DMSO.S188705 |
work_keys_str_mv | AT hinnendeborah cardiovascularrisksintype2diabetesandtheinterpretationofcardiovascularoutcometrials AT krugerdavidaf cardiovascularrisksintype2diabetesandtheinterpretationofcardiovascularoutcometrials |